- Home
- PETS vs ANVS Comparison
PETS vs ANVS Comparison
Compare PETS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ANVS
- Stock Information
- Founded
- PETS 1996
- ANVS 2008
- Country
- PETS United States
- ANVS United States
- Employees
- PETS N/A
- ANVS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ANVS Health Care
- Exchange
- PETS Nasdaq
- ANVS Nasdaq
- Market Cap
- PETS 68.6M
- ANVS 44.6M
- IPO Year
- PETS N/A
- ANVS 2020
- Fundamental
- Price
- PETS $3.19
- ANVS $2.86
- Analyst Decision
- PETS Sell
- ANVS Strong Buy
- Analyst Count
- PETS 2
- ANVS 4
- Target Price
- PETS $3.35
- ANVS $18.00
- AVG Volume (30 Days)
- PETS 127.9K
- ANVS 433.6K
- Earning Date
- PETS 08-05-2025
- ANVS 08-14-2025
- Dividend Yield
- PETS N/A
- ANVS N/A
- EPS Growth
- PETS N/A
- ANVS N/A
- EPS
- PETS 0.02
- ANVS N/A
- Revenue
- PETS $247,010,000.00
- ANVS N/A
- Revenue This Year
- PETS N/A
- ANVS N/A
- Revenue Next Year
- PETS N/A
- ANVS N/A
- P/E Ratio
- PETS $186.94
- ANVS N/A
- Revenue Growth
- PETS N/A
- ANVS N/A
- 52 Week Low
- PETS $2.90
- ANVS $1.11
- 52 Week High
- PETS $6.85
- ANVS $13.91
- Technical
- Relative Strength Index (RSI)
- PETS 37.54
- ANVS 57.81
- Support Level
- PETS $3.32
- ANVS $2.24
- Resistance Level
- PETS $3.49
- ANVS $2.97
- Average True Range (ATR)
- PETS 0.16
- ANVS 0.26
- MACD
- PETS 0.00
- ANVS 0.02
- Stochastic Oscillator
- PETS 16.22
- ANVS 65.58
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.